family with sequence similarity 162 member AGenealiases: C3orf28 · E2IG5 · HGTD-P
Q-omics provides the consensus-scored FAM162A profile across patient tissues and cancer cell-line models. FAM162A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FAM162A is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, FAM162A protein abundance shows 28,979 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, COAD, and LSCC as cancer lineages where FAM162A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM162A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM162A survival associations across molecular data types. FAM162A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM162A RNA expression–survival associations across cancer types. High FAM162A expression shows unfavorable associations in UCS, UCEC and KICH, but favorable associations in LUSC, BLCA and THCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify UCS as the clearest survival context for FAM162A RNA expression.
This table summarizes FAM162A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM162A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM162A shows lower tumor expression in COAD and READ and higher tumor expression in LUAD, BRCA, LUSC and UCEC. The COAD box plot shows higher FAM162A RNA expression in normal versus tumor tissue (log2 FC = −1.415, t-test p < 0.001).
This table shows molecular features associated with FAM162A in patient tissues and cancer cell lines. In patient samples, FAM162A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM162A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
